Proficio Capital Partners LLC Purchases New Position in Illumina, Inc. $ILMN

Proficio Capital Partners LLC purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 5,353 shares of the life sciences company’s stock, valued at approximately $941,000.

Several other large investors have also recently added to or reduced their stakes in the company. Fiduciary Financial Advisors bought a new position in shares of Illumina in the second quarter valued at approximately $26,000. Keating Financial Advisory Services Inc. bought a new stake in Illumina during the 2nd quarter worth approximately $32,000. Rakuten Securities Inc. bought a new stake in Illumina during the 2nd quarter worth approximately $33,000. Elyxium Wealth LLC bought a new stake in Illumina during the 4th quarter worth approximately $25,000. Finally, Elevation Wealth Partners LLC increased its holdings in Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Insider Activity at Illumina

In other Illumina news, Director Keith A. Meister sold 457,858 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the transaction, the director directly owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the transaction, the senior vice president directly owned 21,259 shares in the company, valued at $3,456,500.81. This trade represents a 3.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,799,688 shares of company stock worth $379,517,231 over the last 90 days. Insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on ILMN. Citigroup lifted their price objective on Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research report on Monday, August 3rd. Stifel Nicolaus increased their target price on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. TD Cowen raised their target price on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research note on Friday, July 31st. Deutsche Bank Aktiengesellschaft cut Illumina to a “hold” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $188.40.

Illumina Stock Down 3.0%

NASDAQ:ILMN opened at $207.13 on Wednesday. The stock’s fifty day moving average price is $195.94 and its two-hundred day moving average price is $157.18. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $231.81. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The company has a market cap of $31.28 billion, a price-to-earnings ratio of 38.64, a P/E/G ratio of 3.01 and a beta of 1.44.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period last year, the firm earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.